These are tense times for providers of urine drug tests for Medicare and Medicaid patients. And on Feb. 20, the hot seat got even hotter with the issuance of a new OIG report saying CMS made $66.3 million worth of improper payments for specimen validity tests billed in combination with urine drug tests. Here’s an…
Part B Reimbursement: OIG Flags $66.3 Million in Improper Urine Specimen Validity Test Payments
by Glenn S. Demby | Mar 16, 2018 | CMS-nir, National Lab Reporter, News-nir, OIG-nir, Reimbursement-nir